FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that ...
Artificial intelligence improves process control and reduces the time required to produce key products such as the COVID-19 ...
The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...
16h
Hosted on MSNAltimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 PrintShares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...
The FDA has cleared an Investigational New Drug Application for Zabalafin Hydrogel, a multi-target therapy for mild to ...
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...
TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a ...
The recent notice brings applications for biological products such as vaccines and recombinant deoxyribonucleic acid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results